BIOMAT Database Logo BIOMAT Database Logo

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. 2021

Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Department of GastroenterologyOgaki Municipal HospitalOgakiJapan.

Hepatocellular carcinoma (HCC) can de novo develop in patients with chronic hepatitis C even after the achievement of sustained virologic response (SVR). We characterized de novo HCC after SVR, comparing it with HCC that developed in patients during persistent hepatitis C virus (HCV) infection. Characteristics, survival rates, and recurrence rates after curative treatment in 178 patients who developed initial HCC after SVR diagnosed between 2014 and 2020 were compared with those of 127 patients with initial HCC that developed during persistent HCV infection diagnosed between 2011 and 2015; HCC was detected under surveillance in both groups. HCC was less advanced and liver function worsened less in patients with SVR than in patients with persistent HCV. The survival rate after diagnosis was significantly higher for patients with SVR than for patients with persistent HCV (1-, 3-, and 5-year survival rates, 98.2%, 92.5%, and 86.8% versus 89.5%, 74.7%, and 60.8%, respectively; P < 0.001). By contrast, the recurrence rate after curative treatment was similar between groups (1-, 3-, and 5-year recurrence rates, 11.6%, 54.6%, and 60.4% versus 24.0%, 46.7%, and 50.4%, respectively; P = 0.7484). Liver function improved between initial HCC diagnosis and recurrence in patients with SVR (P = 0.0191), whereas it worsened in the control group (P < 0.001). In addition, patients with SVR could receive curative treatment for recurrence more frequently than patients with persistent HCV (80.4% versus 47.8%, respectively; P = 0.0008). Conclusion: Survival of patients with de novo HCC after SVR was significantly higher than that of patients in whom HCC developed during persistent HCV infection, despite similar rates of recurrence after curative treatment. A higher prevalence of curative treatment for recurrent HCC and improved liver function contributed to this result.

UI MeSH Term Description Entries

Related Publications

Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.
November 2019, Liver international : official journal of the International Association for the Study of the Liver,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.
March 2006, Digestive diseases and sciences,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response.
December 2018, World journal of hepatology,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind.
May 2017, Gastroenterology,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?
August 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
De novo Hepatocellular Carcinoma after Liver Transplantation.
December 2015, Journal of clinical and translational hepatology,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Don't Stop Post-Sustained Virologic Response Hepatocellular Carcinoma Surveillance Just Yet!
December 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
January 2022, Clinics and research in hepatology and gastroenterology,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Methodological Issues on Prediction of Hepatocellular Carcinoma After Sustained Virologic Responses.
June 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Hidenori Toyoda, and Atsushi Hiraoka, and Haruki Uojima, and Akito Nozaki, and Noritomo Shimada, and Koichi Takaguchi, and Hiroshi Abe, and Masanori Atsukawa, and Kentaro Matsuura, and Toru Ishikawa, and Shigeru Mikami, and Tsunamasa Watanabe, and Ei Itobayashi, and Kunihiko Tsuji, and Taeang Arai, and Satoshi Yasuda, and Makoto Chuma, and Tomonori Senoh, and Akemi Tsutsui, and Tomomi Okubo, and Takuya Ehira, and Takashi Kumada, and Junko Tanaka
Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
March 2022, Hepatology communications,
Copied contents to your clipboard!